Defined Health is a leading business development strategy consulting firm. We’ve been assisting clients in the pharmaceutical, biotech and healthcare investment industries for more than 25 years.

  • Defined Health has three core lines of business, each focused on helping companies build and strengthen development-stage assets; compounds, portfolios and platforms
  • A key differentiator is the firm’s focus on defining value for early stage compounds as “proof of relevance” (“PoR”), looking beyond mechanistic proof-of-concept to demonstrate clear potential for clinical differentiation and indisputable commercial value
  • Defined Health’s position of trust can be leveraged for the long term, across the continuum of clinical development and “go to” market services
Opportunity Assessments Portfolio and Platform Strategy Identification and Evaluation of In-Licensing Opportunities
  • Validate scientific rationale
  • Position in evolving standard of care
  • Define target patient populations, clinical endpoints and target product profiles
  • Determine payer perspective
  • Assess commercial value
  • Analyze and prioritize pipeline portfolio
  • Identify and assess novel indications for development
  • Prioritize potential indications
  • Define value inflection strategy for clinical candidates
  • Advise on optimal time and stage of development for partnering
  • Advise on partner selection
  • Establish criteria for identifying programs that fit with strategy
  • Identify assets and/or companies that best match criteria
  • Provide deeper analysis of priority targets
  • Identify value inflection points to optimize partnering strategy
  • Leverage extensive industry network to identify potential strategic partners

Our experience means each new project starts from a solid foundation of knowledge – deep in the therapeutic area, wide in application. Over the past two decades, Defined Health has helped to assess the value of many of the industry's headline partnering deals.

We differ from other consulting firms in our unique depth and breadth of experience, in our people, and in the quality of our client interactions. The key to what we have come to call our unconventional insight is our unparalleled therapeutic area experience.

What's New - Clients in the news

Web Panel Discussion, Part 2: Even More of What's Hot in Immuno-Oncology Licensing (Webinar)
Thursday, December 10, 2015
11am-12:15pm Pacific / 2-3:15pm Eastern

The Future is Now: Dealing in a Transformed Healthcare Environment
LES Annual Meeting
Ed Saltzman, President
November 10, 2015

Web Panel Discussion: What's Hot & What's Not in Immuno-Oncology Licensing
Jeff Bockman, PhD, Vice President
October 6, 2015

Bristol-Myers Squibb, Five Prime enter immuno-oncology deal potentially worth over $1.7 billion

Molecular Partners Receives EUROPEAN BIOTECHNICA AWARD 2015

Heron Therapeutics Soars On Pain Drug Success

Actavis confirms timeline for the start of phase III development of abicipar



Therapeutic Area Partnerships
November 18 - 20, 2015 | Boston, MA

The Life Sciences Summit
December 1 - 2, 2015 | New York, NY

December 5 - 8, 2015 | Orlando, FL

Biotech Showcase 2016
January 11 - 13, 2016 | San Francisco, CA

J.P. Morgan 34th Annual Healthcare Conference 2016
January 11 - 15, 2016 | San Francisco, CA

Cancer Progress by Defined Health
March 8 - 9, 2016 | New York, NY

Therapeutic Insight by Defined Health
April 4 - 6, 2016 | Stockholm, Sweden

AACR Annual Meeting 2016
April 16 - 20, 2016 | New Orleans, LA

May 4 - 7, 2016 | Washington, DC

May 29 - June 2, 2016 | Chicago IL

BIO International Convention
June 6 - 9, 2016 | San Francisco, CA

Pharma CI USA Conference
September 13 - 14, 2016 | Parsippany, NJ

Therapeutic Insight by Defined Health Cancer Progress by Defined Health